- Home
- MX vs BCAB Comparison
MX vs BCAB Comparison
Compare MX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MX | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MX | BCAB |
|---|---|---|
| Price | $2.95 | $0.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.75 | $1.00 |
| AVG Volume (30 Days) | 561.7K | ★ 2.1M |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $224,755,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $2.18 | $0.24 |
| 52 Week High | $5.16 | $1.65 |
Technical Indicators
Market Signals| Indicator | MX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 46.99 |
| Support Level | $2.88 | $0.79 |
| Resistance Level | $3.09 | $0.90 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 85.37 | 12.90 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.